


L Number	Hits	Search Text	DB	Time stamp
1	194	Myers NEAR Michael	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/24 16:29
7	1	(Myers NEAR Michael) and PTEN	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/24 16:29
13	7	daf-18	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/24 16:32
19	244	PTEN	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/24 16:36
25	129	PTEN and phosphatase	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/24 16:33
31	114	(PTEN and phosphatase) and tumor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/24 16:33
49	18	(US-6135942-\$ or US-6472515-\$ or US-6319708-\$ or US-6225120-\$ or US-6284538-\$ or US-6020199-\$ or US-6586181-\$).did. or (US-20010029617-\$ or US-20010016332-\$ or US-20020037585-\$ or US-20030036079-\$ or US-20020058638-\$).did. or (WO-9851351-\$ or WO-9805761-\$ or WO-9902704-\$).did. or (WO-200118549-\$ or WO-9902704-\$ or US-6020199-\$).did.	USPAT; US-PGPUB; EPO; DERWENT	2003/07/24 16:41
56	11	Ruvkun NEAR Gary	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/24 16:43
62	2	wo NEAR "9851351"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/07/24 16:43



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/55, 9/16, A61K 31/70, C07K 16/40, C12Q 1/68, G01N 33/53, C12Q 1/42, A61K 38/46		A2	(11) International Publication Number: WO 99/02704 (43) International Publication Date: 21 January 1999 (21.01.99)
(21) International Application Number: PCT/US98/14205 (22) International Filing Date: 8 July 1998 (08.07.98) (30) Priority Data: 60/051,908 8 July 1997 (08.07.97) US 60/090,984 29 June 1998 (29.06.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/051,908 (CIP) Filed on 8 July 1997 (08.07.97) US 60/090,984 (CIP) Filed on 29 June 1998 (29.06.98) (71) Applicant (for all designated States except US): COLD SPRING HARBOR LABORATORY [US/US]; 1 Bungtown Road, Cold Spring Harbor, NY 11724 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TONKS, Nicholas, K. [GB/US]; 3 Arrowhead Place, Huntington, NY 11743 (US). MYERS, Michael, P. [US/US]; 249 West Nicolai, Hicksville, NY 11801 (US).		(74) Agents: GRANAHAN, Patricia et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	

(54) Title: DUAL SPECIFICITY PHOSPHATASE AND METHODS OF USE



(57) Abstract

PTEN proteins and altered PTEN proteins, and the nucleic acid molecules encoding them are described. Also described are methods of diagnosis and treatment, e.g., of prostate cancer, utilizing compositions comprising PTEN or altered PTEN or nucleic acid molecules encoding PTEN or altered PTEN.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

STEN ④

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : G01N 33/00, C12N 15/00, 15/63, 15/85, 15/86, A61K 38/00	A1	(11) International Publication Number: WO 00/33068 (43) International Publication Date: 8 June 2000 (08.06.00)
(21) International Application Number: PCT/US99/28529 (22) International Filing Date: 2 December 1999 (02.12.99) (30) Priority Data: 09/205,658 3 December 1998 (03.12.98) US (71) Applicant: THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02114 (US). (72) Inventors: RUVKUN, Gary; 120 Herrick Road, Newton, MA 02138 (US). OGG, Scott; 19 Phillips Lane, Newton, MA 02159 (US). (74) Agent: ELBING, Karen, L.; Clark & Elbing L.L.P., 176 Federal Street, Boston, MA 02110-2214 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED GLUCOSE TOLERANCE CONDITIONS (57) Abstract Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.		



US 20010029617A1

(19) **United States**

(12) **Patent Application Publication**
RUVKUN et al.

(10) **Pub. No.: US 2001/0029617 A1**

(43) **Pub. Date: Oct. 11, 2001**

(54) **THERAPEUTIC AND DIAGNOSTIC TOOLS
FOR IMPAIRED GLUCOSE TOLERANCE
CONDITIONS**

(76) **Inventors: GARY RUVKUN, NEWTON, MA
(US); SCOTT OGG, NEWTON, MA
(US)**

**Correspondence Address:
KAREN L ELBING
CLARK & ELBING
176 FEDERAL STREET
BOSTON, MA 02110**

(*) **Notice:** This is a publication of a continued prosecution application (CPA) filed under 37 CFR 1.53(d).

(21) **Appl. No.: 09/205,658**

(22) **PCT Filed: May 15, 1998**

(86) **PCT No.: PCT/US98/10080**

Related U.S. Application Data


(63) Continuation-in-part of application No. 08/888,534, filed on Jul. 7, 1997, now abandoned. Continuation-in-part of application No. 08/857,076, filed on May 15, 1997, now Pat. No. 6,225,120.

Publication Classification

(51) **Int. Cl.⁷** **A61K 49/00; C12N 15/00;
A01K 67/033**
(52) **U.S. Cl.** **800/13; 800/18; 800/3; 435/320.1;
424/9.1; 424/9.2**

(57) **ABSTRACT**

Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.

[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PMC](#)[Taxonomy](#)[OMIM](#)[Books](#)Search for ☒ Limits[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[About Entrez](#)

Show:

Sort

[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation](#)[Matcher](#)[Batch Citation](#)[Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related](#)[Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Privacy Policy](#)☐ 1: Mol Cell. 1998 Dec;2(6):887-93.[Related Articles, Links](#)

The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway.

Ogg S, Ruvkun G.

Department of Molecular Biology, Massachusetts General Hospital, Boston 02114, USA.

An insulin-like signaling pathway, from the DAF-2 receptor, the AGE-1 phosphoinositide 3-kinase, and the AKT-1/AKT-2 serine/threonine kinases to the DAF-16 Fork head transcription factor, regulates the metabolism, development, and life span of *Caenorhabditis elegans*. Inhibition of daf-18 gene activity bypasses the normal requirement for AGE-1 and partially bypasses the need for DAF-2 signaling. The suppression of age-1 mutations by a daf-18 mutation depends on AKT-1/AKT-2 signaling, showing that DAF-18 acts between AGE-1 and the AKT input to DAF-16 transcriptional regulation. daf-18 encodes a homolog of the human tumor suppressor PTEN (MMAC1/TEP1), which has 3-phosphatase activity toward phosphatidylinositol 3,4,5-trisphosphate (PIP3). DAF-18 PTEN may normally limit AKT-1 and AKT-2 activation by decreasing PIP3 levels. The action of daf-18 in this metabolic control pathway suggests that mammalian PTEN may modulate insulin signaling and may be variant in diabetic pedigrees.

PMID: 9885576 [PubMed - indexed for MEDLINE]

Show:

Sort

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act](#) | [Disclaimer](#)

FILE ORDERING
order patent files results



Thursday
7/24/03
2:57:09 PM
WFO1003PR

Serial# 08/888534 File order accepted

Place another order